Abivax S.A.
Close on Oct 19, 2026
About Abivax
Pharmaceutical Preparations, SIC 2834
The entity (operating under the ticker identifier ABVX) operates in biotechnology and therapeutic asset development, conducting research, intellectual property licensing, and contract clinical programs. Its development pipeline centers around project assets such as ABX464 and ABX196, managed in part via licensing contracts and collaborations with research and academic institutions. The filing mentions no retail customer base or direct commercial consumers, indicating an operational emphasis on clinical development, research licensing, and project advancement.
The organization maintains technical facilities and leased premises in Paris, France, where it deploys office equipment, computer software, and specialized operating machinery. In addition to its French infrastructure, the company documents property, contractual relationships, and operations extending across jurisdictions in the United States. No commercial retail stores or store networks are reported in the filing text.
Summary of the business section of Abivax's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Abivax S.A.
- Headquarters
- Paris, France
- Address
- 7 Bd Haussmann
- Phone
- (015) 383-0963
- Website
- abivax.com
- Employees
- 69, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers Audit, Neuilly-sur-Seine, France
Stock & identifiers
- Ticker
- ABVX
- Other tickers
- AAVXF
- Exchange
- Nasdaq
- IPO date
- Oct 23, 2023
- Shares outstanding
- 79M, Dec 31, 2025
- Filer category
- Accelerated filer<br>Emerging growth company
- SEC CIK
- 1956827
- CUSIP
- 00370M103
- ISIN
- US00370M1036
- LEI
- 969500D8TMNB184OJU95
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Abivax's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 69 full-time employees, consisting of 49 within the research and”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 23, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 18, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |